Saltroad Closes £1.5M and Buys Ogma to Scale UK Speech Therapy

Saltroad, the Northern Ireland-based private speech and language therapy marketplace, has raised £1.5 million and acquired Ogma, the London-based AI documentation platform that built its name on clinical scribes for paediatric speech therapists. Techstart Ventures led the round, with Ascension, ScaleX and a group of named angel investors on the cap table alongside it.

The deal wraps the start-up’s two-track thesis into one transaction: a clinician-led marketplace of more than 1,000 NHS-registered private therapists, now paired with a purpose-built scribe that handles the paperwork that has been swallowing therapists’ weeks.

A £1.5M Round That Closed With an Acquisition

Saltroad confirmed this week a £1.5M funding round led by Techstart Ventures, with participation from Ascension, ScaleX and a group of prominent angel investors. The Belfast-headquartered company framed the capital as a way to scale a private speech and language therapy marketplace across the UK, and tied the deal to the acquisition of Ogma.

It is Saltroad’s second institutional round. The company previously raised £575,000 in pre-seed funding in July 2024, also led by Techstart Ventures alongside Ascension VC, per UK Tech News coverage of that earlier round. Founders Darren and Debi Lester, who appear side-by-side on Saltroad’s company page on the paediatric SLT mission, built the firm on the back of a 2021 sale of Darren Lester’s prior venture, SpecifiedBy.com, and Debi Lester’s twelve-plus years of NHS and private speech and language therapy work.

Too many children wait months, sometimes years, for help during the years that matter most. That isn’t a failure of effort from therapists – it’s a system that was never built for the scale or variety of need it now faces. Saltroad exists to put the therapy back into speech and language therapy, and to reach the families the current systems can’t. This funding, and the Ogma acquisition, supports how we build that and deliver tailored, 1:1 speech therapy at scale.

Ogma arrives as the structured half of the deal rather than a stand-alone raise. The London-based AI company was founded in 2023 by Dr Cole Robertson and had been unfunded until the acquisition per the Tracxn company profile; its first product has been a clinical scribe. Saltroad’s £1.5M headline figure is corroborated by Seedtable’s tracked total funding figure of £1,480,000 as of 11 June 2026. The pitch, in CEO Lester’s words, is to put clinician time back in front of children, not to replace clinicians with software.

Pairing Families With the Right Private Therapist

Saltroad’s mechanism is a curated private marketplace. Parents complete a short screener, then get matched to NHS-registered therapists based on the child’s clinical needs, the family’s budget and schedule. The platform explicitly removes the NHS waiting list from the path for families who can pay out of pocket.

• No NHS waiting list: matches are made on therapist availability
• Clinically matched: therapists are selected for the child’s clinical needs, not on postcode
• Wider pool: access to a larger set of NHS-registered specialists than any one local NHS service could offer
• Lower cost than traditional private therapy, per the company’s pitch

The start-up’s own About page describes the children’s speech therapy crisis as a “hidden pandemic,” noting that “as many as 1 in 5 children in the UK may need help from a Speech and Language Therapist today (over 2 million kids).” It also says NHS waiting lists for SLT have stretched past two years in some areas. Saltroad sits in the gap between a stretched NHS and a postcode-lottery private market, with a matching layer that, in the company’s framing, restores clinical time per child rather than thinning it.

What Ogma Does During a Session

Ogma’s first product is a clinical scribe. The platform listens during a therapy session, drafts the structured notes a therapist would normally write up after hours, and monitors patient progress across visits. The company’s investor announcement on the topic, written by investor Jem Stein, describes the product as one that “will save many hours of time for therapists and allow them to focus on delivering more for their patients.” The Ogma app is live, with its first users onboard and an NHS trial underway, according to the same Ogma announcement by investor Jem Stein.

Underneath the scribe sits a phoneme-level speech recognition engine built specifically for children’s speech, including atypical speech. The same announcement describes the engine as “a world first,” a claim scoped to children’s speech recognition. The platform’s founder, Dr Cole Robertson, has built it for the kind of paediatric caseload that adult-tuned speech-to-text systems misread or miss.

Inside Saltroad’s network of over 1,000 therapists, Ogma’s job is to standardise documentation across a workforce that varies in setting, caseload mix and note-taking convention. Therapists get back the after-hours administrative hours they currently eat into family time. The intended effect is throughput: more children per therapist per week, without lowering the clinical bar that Saltroad pitches to families. That last clause, “without lowering the bar,” is also the line Toyosi Ogedengbe of Ascension uses to defend the bet in his own statement on the round.

The 1 in 5 Children Behind the Bet

Saltroad anchors the size of the prize in its own framing of the country: 1 in 5 children in the UK may need speech and language therapy today, which the company puts at “over 2 million kids.” That figure is consistent with the UK Tech News reporting on the earlier round, which cited the same “two million children” estimate from the SLT UK charity. The company frames the gap as a “hidden pandemic” on its About page, describing “an exponential increase in children who need support with their speech, language and communication.”

A briefing by the Nuffield Trust, published as part of its QualityWatch programme with the Health Foundation, found that the community care waiting list for children has grown 58% since data collection began in 2022. The same analysis found that 21% of children on those lists are waiting specifically for speech and language therapy services. Almost 1 in 4 children on community waiting lists wait more than a year, and 1 in 15 wait more than two years, against a 1-in-100 rate for adults. The structural gap is hard to close with a single NHS expansion; Saltroad’s bet is that private and AI-augmented capacity absorbs it, per the Nuffield Trust briefing on rising community care waits for children.

The human cost of the wait usually falls on families. BBC reporting on this stretch of NHS community waits told the story of Tiya Currie, from London, whose son Arun waited two years for NHS speech and language therapy before the family used £4,000 of savings to go private and reach a formal developmental language disorder diagnosis. Her experience is what Saltroad is selling against.

300,000 children on community waiting lists gives the addressable population a floor, not a ceiling. SLT UK puts the wider need at two million, the same figure Saltroad uses on its company About page. The deal lands in a market that is structurally short of supply and growing demand at the same time, which is what every investor quote this round comes back to.

Why Three Investors Are Doubling Down

Both lead investors from Saltroad’s 2024 pre-seed round are back. Techstart Ventures and Ascension were the two named investors on the £575k pre-seed; both have written checks again for the £1.5M round, and both have expanded the syndicate to ScaleX and a group of named angels. That is a signal of deepening, not rotation.

The case on offer is a clinician-first one, dressed up as a workforce-plus-AI combination. Audrey Osborne, Partner at Techstart Ventures, is the most direct on it. Toyosi Ogedengbe of Ascension widens the same lens, saying Ascension looks for teams solving problems that genuinely matter at scale, and that bringing AI alongside skilled clinicians, rather than in place of them, is the right way to widen access without lowering the bar.

We’ve backed Saltroad since inception, and everything since has deepened our conviction in Darren, Debi and the team. The combination of a scalable therapist workforce and purpose-built AI is exactly the kind of ambition we want to support in Northern Ireland.

Ogedengbe’s framing sits at the heart of Saltroad’s commercial pitch. The start-up’s stated goal is to increase the number of children each therapist can see without compromising clinical quality or therapist wellbeing. The Ogma scribe is the lever. The therapist workforce of over 1,000 is the substrate. Both numbers were named by Saltroad, by Tracxn’s tracked funding, and by Techstart and Ascension’s joint returns to the cap table.

Frequently Asked Questions

What is Saltroad?

Saltroad is a Northern Ireland-headquartered, clinician-led private speech and language therapy marketplace founded by Darren and Debi Lester. It connects families with NHS-registered speech and language therapists and has previously been backed by Techstart Ventures and Ascension.

What is Ogma and what does it do?

Ogma is a London-based AI platform founded in 2023 by Dr Cole Robertson and focused on paediatric speech and language therapy. Its phoneme-level speech recognition engine is built for children’s speech, and its first product is a clinical scribe that drafts session notes and tracks patient progress.

How much has Saltroad raised?

Saltroad has raised £575,000 in a 2024 pre-seed round led by Techstart Ventures and Ascension VC, followed by a £1.5M round announced with the Ogma acquisition. Seedtable tracked total funding at £1,480,000 as of 11 June 2026.

How big is the NHS speech therapy waiting list?

BBC analysis found about 300,000 children on NHS community waiting lists in England, with more than 77,500 waiting over a year. The Nuffield Trust says 21% of children on community paediatric waiting lists are waiting specifically for speech and language therapy, and almost 1 in 4 children wait over a year for community care.